Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Onconetix has extended a bridge financing facility of up to $5 million to Realbotix LLC, the target of its pending all-stock acquisition, with an initial advance of $2.5 million to fund Realbotix's growth and working capital while the deal advances toward closing. The facility is non-interest bearing before closing. If the Share Exchange Agreement closes, the note is automatically cancelled and discharged in full, and the cash required at closing is reduced by the total principal advanced plus an additional $500,000. If the deal is terminated instead, interest accrues at 12% per annum from the termination date.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.